SUBSCRIBE
SUBSCRIBE
News   FDA

Amgen Blood-clotting Drug Decision Delayed

July 23, 2008 | 
1 min read
NEW YORK - Biotechnology company Amgen Inc. said Wednesday the Food and Drug Administration will not issue a much anticipated decision this week on whether to approve an experimental blood-clotting disorder drug.
FDA Approvals Regulatory
Amgen
MORE ON THIS TOPIC
Email envelope with warning sign on white background
Manufacturing
FDA sends warning letter after Chinese supplier breaks GLP-1 import restrictions
May 20, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Richard Pazdur
Regulatory
Pazdur declines to announce candidacy for vacated FDA commissioner role
May 20, 2026
 · 
4 min read
 · 
Heather McKenzie
FDA
FDA’s absent leaders, the millions pharma CEOs make, and pancreatic cancer’s momentum
May 20, 2026
 · 
1 min read
 · 
Jef Akst
The COVID-19 vaccine in glass bottles for prevention, immunization, and treatment of coronavirus infection on a green background. Space for text. Concept of medical and vaccine.
COVID-19
FDA’s own report shows no child deaths definitively caused by COVID vaccination
May 19, 2026
 · 
3 min read
 · 
Tristan Manalac